Table 1 Baseline characteristics
|  | Camrelizumab + fuzuloparib + apatinib 375 mg (n = 3) | Camrelizumab + fuzuloparib + apatinib 500 mg (n = 29) |
|---|---|---|
Age, median (range), years | 42 (37–49) | 54 (39–72) |
ECOG performance status | ||
 0 | 2 (66.7) | 20 (69.0) |
 1 | 1 (33.3) | 9 (31.0) |
Metastasis | ||
 Yes | 0 | 4 (13.8) |
 No | 3 (100.0) | 22 (75.9) |
 Unknown | 0 | 3 (10.3) |
Previous neo-(adjuvant) chemotherapy | ||
 Yes | 3 (100) | 29 (100) |
 No | 0 | 0 |
Previous palliative chemotherapy | ||
 Yes | 3 (100.0) | 15 (51.7) |
 No | 0 | 14 (48.3) |
No. of prior palliative therapies | ||
 1 | 2 (66.7) | 9 (31.0) |
 2 | 0 | 3 (10.3) |
 3 | 1 (33.3) | 2 (6.9) |
 4 | 0 | 1 (3.4) |
Previous taxane and anthracycline treatment | ||
 Taxane | 3 (100.0) | 28 (96.6) |
 Anthracycline | 3 (100.0) | 27 (93.1) |